Introduction
The incidence of heart failure (HF) increases with age, and HF is a common disease of elderly patients [1, 2] . Data on HF in patients aged less than 50 years are limited [1, 3, 4] . Three studies reported on the characteristics and clinical outcome of younger patients with chronic HF, which indicate a distinct phenotype, typically comprising non-ischemic etiology, more severe left ventricular dysfunction and less concomitant comorbidities compared to older patients [5] [6] [7] [8] [9] [10] .
Most studies in AHF focus on the elderly [3, 4] . However, the specific characteristics and the clinical outcome of young patients who are hospitalized for acute HF (AHF) are currently not well described. Therefore, we sought to characterize differences in baseline characteristics, management, and clinical outcomes of young patients compared to older patients hospitalized for AHF. In addition, we studied biomarkers from different pathophysiological domains in young versus older patients to gain insight in underlying differences in pathophysiology.
Methods.

Study design and population
The Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor
Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart
Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal FuncTion (PROTECT) was a multicenter, randomized, placebo-controlled trial for which the design and primary results have previously been published [11] [12] [13] . In brief, PROTECT included 2033 patients hospitalized for AHF with impaired renal function (estimated creatinine clearance between 20 and 80ml/min), signs and symptoms of fluid overload, concomitant dyspnea, NYHA III-IV symptoms, systolic blood pressure ≥ 95mmHg, who required i.v. diuretic therapy. Overall results of the PROTECT trial were neutral and have been previously reported [11, 13] . This study complied with the Declaration of Helsinki and was approved by local Ethics Committees. All patients provided written informed consent.
Definitions and endpoints
Patients younger than or equal to 50 years were classified as "young"; whereas the remainder of patients was referred to as older (>50 years) in accordance with previous publications [3, 5] . HF with preserved ejection fraction (HFpEF) was defined as left ventricular ejection fraction (LVEF) >45% based on available echocardiographic data in 976 patients. The total diuretic dose through day 4 was defined as the sum of the daily oral (p.o.) and intravenous (i.v.) diuretic doses, weighing the effects of i.v. loop diuretics with the factor 1 and those of p.o. loop diuretics with the factor 0.5.
The primary and secondary endpoints of PROTECT have previously been described in detail [11, 12] . We assessed the primary pre-specified trichotomous endpoint, a classification of therapy response into ''success'' (Improvement in dyspnea (7-point Likert scale) without treatment failure), ''failure'' (Death or readmission for heart failure to day 7, worsening heart failure symptoms from >1 to 7 days after treatment, requiring rescue therapy, or persistent renal impairment) or ''unchanged'' across age groups. Additionally, the secondary end points 60-day death and hospitalizations, 60-day death or rehospitalization, 60-day death or HF rehospitalization, 60-day HF rehospitalization, 60-day death, cardiovascular or renal rehospitalization and 180-day mortality were analyzed. An independent endpoint committee adjudicated all rehospitalizations through day 60 and deaths through day 180.
Biomarkers
Of the 2033 patients in PROTECT, 1266 patients had complete biomarker data available at baseline. Forty-eight biomarkers were assessed for the present analysis.
Blood urea nitrogen (BUN) and creatinine, were measured in a central laboratory Immunoassays to PCT, proADM, Galectin-3 and ST2 were developed by Alere.
These research assays have not been standardized to the commercialized assays used in research or in clinical use and the extent to which each Alere assay correlates with the commercial assay is not fully characterized (supplementary table   1 ).
Additionally, a panel of four biomarkers -Endothelin-1 (ET-1), Interleukin-6 (IL-6), Kidney Injury Molecule 1 (KIM-1) and cardiac specific Troponin I (cTnI) was measured in frozen plasma samples collected at baseline using high sensitive single molecule counting (SMC™) technology (RUO, Erenna® Immunoassay System, Singulex Inc., Alameda, CA, USA) (see supplementary methods for details). Nterminal pro-brain natriuretic peptide (NT-proBNP) was measured during screening using commercial assays available at the study centers or a point of care device provided to study sites when needed.
Statistical analyses
Summary baseline statistics for continuous variables are presented as mean with standard deviation or median with interquartile range as appropriate, and proportions for categorical variables.
Equality of the means of continuous, normally distributed variables across age groups were tested using Students' t-test. Equality of ranks of continuous, skewed distributed variables across age groups were tested using the Mann-Whitney-U test.
Independent distributions of frequencies in categorical variables between age groups were tested using Pearson's chi-squared test.
Statistical analyses were performed using STATA (version 13.1. STATA Corp.
College Station. TX. USA). Two-sided P-values < 0.05 were considered statistically significant.
Results
Baseline characteristics. Table 1 shows the baseline demographic and clinical characteristics in both age groups.
A total of 121 (6%) patients in PROTECT were younger than 50 years, with a mean age of 43.9±6.4 years. Young patients were predominantly men, had a higher body mass index and higher estimated glomerular filtration rate, while having lower left ventricular ejection fraction, lower systolic blood pressure and higher heart rate compared to older patients. They had lower rates of ischemic heart disease, atrial fibrillation, hypertension, stroke and peripheral vascular disease. However, the proportion of patients with a history of HF and hospitalization for HF during the previous year was higher in young patients.
Details on medication, non-pharmacological therapy and treatment response during hospitalization are presented in table 2 and figure 1. Younger patients were more often treated with beta-blockers and mineral receptor antagonists, and less often with nitrates and calcium channel blockers. Additionally, mineral receptor antagonists were more often initiated and/or their doses were more often increased in young patients during hospitalization (figure 1).
Outcomes
Young patients were treated with higher IV and oral loop diuretic doses during hospitalization (table 2) than older patients. From admission to day 4, young patients showed the higher absolute weight loss, while diuretic response was similar compared to the older patients. Additionally, young HF patients showed lower rates of worsening renal function (WRF) (5.8% vs. 15.3%, p=0.004) (table 2).
The primary pre-specified trichotomous endpoint did not differ across the age groups, albeit that young AHF patients were more frequently readmitted for HF, but less often showed serum creatinine increase and persistent renal impairment (table   3) . Young patients had lower 180-day mortality (9.9% vs. 18.1%, p=0.021) (table 3).
HF / pump failure was the most frequent cause of death in young patients (table 3) .
Biomarker profiles
The levels of biomarkers at baseline are shown in table 4. Younger patients had lower levels of IL-6, PIGR, TNFR1A, WAP4C, galectin 3, mesothelin, LTBR, ESAM-1, BUN, NGAL and KIM-1. In contrast, VEGFR1 and angiogenin were higher in young patients.
Discussion
This study provides a comprehensive overview of clinical characteristics, in-hospital management, clinical outcomes and biomarker differences between young and older AHF patients. Young patients had distinct signs and symptoms of acute HF at hospital admission compared to the elderly. Furthermore, during hospitalization young patients were treated with higher diuretic doses, which led to a similar diuretic response. However, diuretic treatment was accompanied by less WRF during hospitalization. Biomarker levels significantly differed between both age groups.
Compared to older patients, the young AHF patients mainly exhibited lower levels of biomarkers indicative of inflammation and renal damage.
Overall, young patients showed a typical pattern of signs and symptoms of AHF at admission, which confirms previous reports in a chronic setting [5, 6] . They less frequently had rales, dyspnea and angina, but a higher jugular venous pressure.
Young patients with AHF had a more favorable clinical profile with less comorbidities, less ischemic etiology and less renal dysfunction than older patients, as previously reported in patients with chronic heart failure [5] . Although several other studies explored the clinical features of acute heart failure and their relationship with patient age, these studies primarily focused on the characteristics of elderly patients, rarely included patients younger than 50 years of age and are limited to only few standard blood biomarkers [4, 7, 14] . Importantly, Metra et al. previously analyzed the influence of age on patient characteristics and outcome. He found that with increasing age, patients more often exhibited characteristics such as female sex, hypertension, atrial fibrillation, and higher left ventricular ejection fraction. This was paralleled by independent increased risk of adverse 30-and 180-day outcomes [4] .
In our study, young patients had higher estimated glomerular filtration rates at admission, and during hospitalization for AHF they experienced less persistent WRF.
The less impaired renal function at baseline is typical for younger compared to older patients with acute heart failure and could in part explain that during diuretic therapy, young patients less frequently developed WRF than older HF patients [15] . Young HF patients were treated with higher doses of diuretics and showed more weight loss. Interestingly, a recent sub-analysis of the EVEREST trial showed that a worse congestion status during AHF hospitalization was associated with worse outcomes [16] . The data from this study suggest that the better diuretic response of the young patients in our study is related to a better renal function, which translates to more favorable outcomes with regard to the primary endpoint.
We used biomarkers to better characterize acute heart failure in the young.
Overall, young patients had lower levels of inflammatory markers. There is a clear pattern of lower median values of inflammatory biomarkers in the younger patients as opposed to older patients, although only few biomarkers, such as IL-6, TNFR1A, LTBR and WAP4C, reached the statistical significance level. The lower level of inflammation can potentially be explained by the fact that younger patients suffer from less comorbidities and more often had HFrEF [17] [18] [19] . It has been hypothesized that comorbidities, such as COPD and aging, contribute to a general proinflammatory state, which is accompanied by higher levels of inflammation markers and more prevalent in the elderly [20, 21] . This also holds true for our data, where young AHF patients had more HFrEF and fewer comorbidities compared to their elder peers. Notably, this effect can be detected despite the higher body mass index in the younger patients. Although it is known that obesity should actually be associated with an increase in biomarkers of inflammation, our study shows that the level of inflammation in younger patients with acute decompensated heart failure is lower than that of older patients.
Furthermore, biomarkers associated with poor renal function (BUN, NGAL, KIM-1, galectin-3) were lower in younger patients [22] [23] [24] [25] [26] . This correlates with the finding that younger patients overall had a better renal function at admission and were less often subject to WRF during hospitalization.
Angiogenesis markers had a heterogeneous distribution across both age groups. Levels of endothelial cell-selective adhesion molecule (esam-1), an endothelial dysfunction marker, were found to be lower in the young; this likely reflects that the young less often had a history of myocardial infarction and ischemic heart disease [27] . Indeed, higher levels of esam-1 were previously found to be associated with arteriosclerosis [27] . Additionally, higher esam-1 levels were shown to be independently associated with impaired renal function [28] . Furthermore, mesothelin levels were previously found to be higher in patients with impaired renal function, which is in accordance with our results [29] . Angiogenin and VEGFR1, which had the highest levels in young patients, were linked to angiogenesis and revascularization [30] [31] [32] [33] . Both markers are pathophysiologically involved in vascular repair and cardiac remodeling, both of which are etiological factors for the development of HFrEF. Angiogenesis is impaired in the elderly, possibly also contributing to the lower levels of these two biomarkers in the older patients [33] .
The main clinical implication of our findings is that younger patients with AHF are a distinct subgroup. Young patients can be decongested more aggressively at lower risk of worsening renal function with anticipated better outcomes than older patients with AHF. Biomarkers reflect a characteristic pattern of pathophysiological processes in young patients.
Limitations
A limitation of our study is the relatively small sample size of patients' younger than 50 years of age and the misbalance compared to the much larger group of older patients, which could introduce bias to the detected differences. Additionally, as a post hoc study, a possible selection bias may be present. Lastly, the main PROTECT trial was not primarily designed to assess mortality.
Conclusions.
Despite being treated with higher dosage of diuretic therapy, young AHF patients develop less WRF compared to their older peers during hospitalization. Clinically, young AHF patients in the PROTECT dataset had lower LVEFs, fewer comorbidities and a lower rate of HFpEF. Biomarkers potentially reflect these pathophysiological differences between young and older AHF patients. 
In-hospital outcome
Worsening renal function, % Dyspnea reported by the patient using a 7-point Likert scale as moderately or markedly better compared with study start, AND Not a treatment failure †, Patient unchanged: Neither treatment success nor treatment failure ‡, Death or readmission for heart failure any time through Day 7 §, Worsening symptoms and/or signs of heart failure occurring >24 hours after the start of study drug to Day 7 or discharge, whichever occurs first, such that there is a need for any one of the following types of ''rescue therapy'': an increase in the dose or reinstitution of IV loop diuretic therapy, or initiation of oral metolazone or IV chlorothiazide as accompanying therapy to loop diuretics initiation of ultrafiltration initiation of IV positive inotropes, vasopressors, or IV vasodilators initiation of mechanical ventilatory (including BiPAP or CPAP) or circulatory support | |, Persistent renal impairment as defined by a serum creatinine increase of ≥0.3 mg/dL (25.5 umol/L) from randomization to Day 7, confirmed at Day 14, or the initiation of hemofiltration or dialysis through Day 7 
